New Alzheimer’s disease drugs designed to target neuroinflammation

Written by Ellen Clarke

For many years neuroinflammation has been thought to be a key player in the pathogenesis of Alzheimer’s disease (AD). However, in the early 2000’s a number of anti-inflammatory treatment studies yielded negative results. Recently there has been renewed interest in the role of neuroinflammation as a driver of AD, and its potential as a therapeutic target. This was apparent at the 8th International Conference on Clinical Trials for Alzheimer’s Disease (5–7 November 2015, Barcelona, Spain), where anti-inflammatory treatments took centre stage. “The field languished for at least a decade, until three years ago when intriguing findings about genetic risks for...

To view this content, please register now for access

It's completely free